Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...

The company’s Phase III trial of nemvaleukin alfa alongside Keytruda saw just a 0.3 month gain in overall survival over other ...

Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Mural Oncology in a research ...

Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials ...

H.C. Wainwright analyst Andres Maldonado lowered the firm’s price target on Mural Oncology (MURA) to $6 from $18 and keeps a Buy rating on the ...

Mural Oncology (NASDAQ:MURA – Get Free Report) was downgraded by stock analysts at Raymond James from a “strong-buy” rating ...

A Waltham company pulled the plug on a Phase 3 cancer trial, while a different Waltham company continued its leadership ...

Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement in ...

Mural Oncology (NASDAQ:MURA) stock plummets 47% as the company, a spinoff of Alkermes (ALKS) halts a Phase 3 trial for its ...

WALTHAM, Mass - Mural Oncology plc (NASDAQ:MURA), a clinical-stage biopharmaceutical company valued at approximately $66 million, has announced the discontinuation of its phase 3 ARTISTRY-7 trial for ...